gracecast-144_lung_highlights in lung cancer, 2013: mek inhibitors for kras mutation-positive nsclc
Published 11 years ago • 644 plays • Length 5:27Download video MP4
Download video MP3
Similar videos
-
8:06
gracecast-145_lung_highlights in lung cancer, 2013: squamous cell nsclc and antipd1
-
5:11
gracecast-114_lung-cancer_asco 2012 lc highlights: dr. neal on mek inhibitor selumetinib in nsclc
-
18:51
gracecast-140_lung_highlights in lung cancer, 2012: new options for egfr mutation-positive nsclc
-
3:43
gracecast-146_lung_highlights in lung cancer, 2013: maintenance therapy in advanced nsclc
-
5:58
gracecastuc-017_lung_a promising option for people with the most common lung cancer mutation?
-
4:04
can we target kras effectively in advanced nsclc?
-
10:37
gracecast-141_lung_highlights in lung cancer, 2012: alk inhibitors for patients with alk or ros1
-
11:13
gracecast-091_lung-cancer_highlights 2011: the egfr axis
-
13:40
gracecast-104_lung-cancer_immunotherapy for lung cancer: q and a session
-
33:47
gracecast-049_lung-cancer_weiss on egfr therapy for early stage nsclc
-
16:39
gracecast-067_lung-cancer_expert round table - nsclc molecular markers case 3
-
20:34
gracecast-118_lung-cancer_asco 2012 lung cancer highlights: question and answer session
-
7:09
gracecast-111_lung-cancer_asco 2012 lc highlights: dr. socinski on tailor trial in advanced nsclc
-
5:13
gracecast-115_lung-cancer_asco 2012 lc highlights: dr. neal on lux-lung 3 trial for advanced nsclc
-
9:30
gracecast-037_lung-cancer_horton interview 1 - nsclc subtypes
-
14:43
gracecast-070_lung-cancer_q&a for acquired egfr tki and re-biopsying
-
8:22
gracecast-093_lung-cancer_highlights 2011: alk and new molecular targets
-
10:02
gracecast-137_ca-101-_dr. ramalingam: q and a session on clinical trials in oncology
-
11:29
gracecast-069_lung-cancer_sequist on results from re-biopsying lesions